Abstract
Tumor-induced immunosuppression is a fundamental problem in cancer immunotherapy and can occur by a variety of cellular and molecular mechanisms, affecting all arms of the immune system. Tumorproduced or elicited factors have been shown to inhibit antigen-specific immune effector function as well as impairment of the development, recruitment and maturation of dendritic cells (DCs) and T cells. A better understanding of the cross-talk between tumors and tumor-associated DCs and T cells is necessary to develop novel approaches for cancer immunotherapy. The recruitment of DCs to tumors, antigen processing and presentation, and migration of antigen-loaded DCs to secondary lymphoid organs are perturbed in tumorbearing hosts. The ability of tumor-associated DCs to induce an anti-tumor response may be prevented by the tumor microenvironment due to inhibitory factors such as vascular endothelial growth factor (VEGF)-C, which are also known to regulate tumor angiogenesis and lymphangiogenesis. Strategies to inhibit tumor-induced angiogenesis and immunosuppression provide therapeutic approaches with the potential for synergism. In this review we will discuss the possibilities of developing novel approaches to concurrently inhibit angiogenesis, inhibit lymphangiogenesis, eliminate tumor-induced immunosuppression and augment the anti-tumor immune as potent multi-modality therapeutic strategies for metastatic cancer.
Current Molecular Medicine
Title: Lymphangiogenesis and Anti-Tumor Immune Responses
Volume: 9 Issue: 6
Author(s): Michelle L. Varney, Seema Singh, Matthew Backora, Zhengtang Chen and Rakesh K. Singh
Affiliation:
Abstract: Tumor-induced immunosuppression is a fundamental problem in cancer immunotherapy and can occur by a variety of cellular and molecular mechanisms, affecting all arms of the immune system. Tumorproduced or elicited factors have been shown to inhibit antigen-specific immune effector function as well as impairment of the development, recruitment and maturation of dendritic cells (DCs) and T cells. A better understanding of the cross-talk between tumors and tumor-associated DCs and T cells is necessary to develop novel approaches for cancer immunotherapy. The recruitment of DCs to tumors, antigen processing and presentation, and migration of antigen-loaded DCs to secondary lymphoid organs are perturbed in tumorbearing hosts. The ability of tumor-associated DCs to induce an anti-tumor response may be prevented by the tumor microenvironment due to inhibitory factors such as vascular endothelial growth factor (VEGF)-C, which are also known to regulate tumor angiogenesis and lymphangiogenesis. Strategies to inhibit tumor-induced angiogenesis and immunosuppression provide therapeutic approaches with the potential for synergism. In this review we will discuss the possibilities of developing novel approaches to concurrently inhibit angiogenesis, inhibit lymphangiogenesis, eliminate tumor-induced immunosuppression and augment the anti-tumor immune as potent multi-modality therapeutic strategies for metastatic cancer.
Export Options
About this article
Cite this article as:
Varney L. Michelle, Singh Seema, Backora Matthew, Chen Zhengtang and Singh K. Rakesh, Lymphangiogenesis and Anti-Tumor Immune Responses, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970733
DOI https://dx.doi.org/10.2174/156652409788970733 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Celastrus Orbiculatus Extract Potentiates the Sensitivity of Cisplatin Via Caspase-Depenent Apoptosis in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Natural Products and Cancer Stem Cells
Current Pharmaceutical Design The Dichloromethane Fraction of <i>Vernonia cinerea</i> Impart Pro-Apoptotic, Genotoxic, Cell Cycle Arrest, and Drug Efflux Inhibitory Effects on Human Adenocarcinoma Cells
Recent Patents on Anti-Cancer Drug Discovery Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma
Current Cancer Drug Targets Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Identification of Leads from Marine Seaweeds against Human β-tubulin
Letters in Drug Design & Discovery Microbicides for Prevention of Transmission of Sexually Transmitted Diseases
Current Pharmaceutical Design Autism Spectrum Disorder Detection with Machine Learning Methods
Current Psychiatry Research and Reviews GPER Overexpression in Cervical Cancer Versus Premalignant Lesions: Its Activation Induces Different Forms of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Tissue-Specific Methylation of Long Interspersed Nucleotide Element-1 of Homo Sapiens (L1Hs) During Human Embryogenesis and Roles in Neural Tube Defects
Current Molecular Medicine Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Immunological Aspects of Metritis in Dairy Cows: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry